Opinion|Videos|July 16, 2024
Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.
Advertisement
Episodes in this series
- How redefining SCLC as a molecularly heterogeneous malignancy might better inform personalized treatment of its subtypes with unique therapeutic vulnerabilities.
- How the mechanism of promoter methylation levels in ctDNA subtypes contribute to “subtype switching” in relapsed SCLC.
- Potential contribution of subtype switching to treatment resistance (platinum-based chemotherapy)
- How ‘switching’ to an inflammatory phenotype might improve therapeutic response to immune checkpoint inhibitors vs other SCLC subtypes
- The variable response of SCLC subtypes to currently available therapies
- Briefly discuss significant adverse events in patients with LS-SCLC who receiveIO-based regimens and explore strategies for their mitigation and management.
Advertisement
Related to this article
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
Dr Kuykendall on the Significance of the FDA Approval of Rusfertide for Polycythemia Vera
5